[go: up one dir, main page]

NO20091247L - terapeutiske pyrazolyl tienopyridiner - Google Patents

terapeutiske pyrazolyl tienopyridiner

Info

Publication number
NO20091247L
NO20091247L NO20091247A NO20091247A NO20091247L NO 20091247 L NO20091247 L NO 20091247L NO 20091247 A NO20091247 A NO 20091247A NO 20091247 A NO20091247 A NO 20091247A NO 20091247 L NO20091247 L NO 20091247L
Authority
NO
Norway
Prior art keywords
therapeutic
thienopyridines
pyrazolyl
compounds
formula
Prior art date
Application number
NO20091247A
Other languages
English (en)
Inventor
Stephen Douglas Barrett
Huifen Chen
Mark Laurence Boys
James B Kramer
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20091247L publication Critical patent/NO20091247L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Det beskrives forbindelser av formel 1, og farmasøytisk akseptable er derav, hvor R1,R2, R2, R4, R5, R6 og R7 har de betydninger som er gitt her i beskrivelsen, og farmasøytisk akseptable salter derav, som er nyttige som terapeutiske midler i behandlingen av TGFß, samt sammensetninger omfattende en eller flere forbindelser av formel I.
NO20091247A 2006-10-16 2009-03-25 terapeutiske pyrazolyl tienopyridiner NO20091247L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85198206P 2006-10-16 2006-10-16
PCT/IB2007/002994 WO2008047198A1 (en) 2006-10-16 2007-10-04 Therapeutic pyrazolyl thienopyridines

Publications (1)

Publication Number Publication Date
NO20091247L true NO20091247L (no) 2009-04-23

Family

ID=38962671

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091247A NO20091247L (no) 2006-10-16 2009-03-25 terapeutiske pyrazolyl tienopyridiner

Country Status (16)

Country Link
US (5) US7964612B2 (no)
EP (2) EP2074128B1 (no)
JP (1) JP5443988B2 (no)
KR (1) KR20090066297A (no)
CN (1) CN101528752A (no)
AR (1) AR063318A1 (no)
AU (1) AU2007311560B2 (no)
CA (1) CA2666603C (no)
CL (1) CL2007002916A1 (no)
ES (2) ES2559521T3 (no)
IL (1) IL197750A0 (no)
MX (1) MX2009003157A (no)
NO (1) NO20091247L (no)
TW (1) TW200825094A (no)
UY (1) UY30641A1 (no)
WO (1) WO2008047198A1 (no)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101528752A (zh) 2006-10-16 2009-09-09 辉瑞产品公司 治疗性吡唑基噻吩并吡啶
WO2009089324A1 (en) 2008-01-08 2009-07-16 Yale University Compositions and methods for promoting patency of vascular grafts
FR2949468B1 (fr) * 2009-08-28 2011-09-30 Sanofi Aventis Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur preparation et leur application en therapeutique
FR2940652B1 (fr) * 2008-12-29 2011-02-11 Sanofi Aventis Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one,leur preparation et leur application en therapeutique
AU2009334570B2 (en) * 2008-12-29 2016-06-09 Sanofi Derivatives of 2-pyridin-2-yl-pyrazol-3(2h)-one, preparation and therapeutic use thereof
ES2481042T3 (es) 2008-12-29 2014-07-29 Sanofi Derivados de 2-piridin-2-il-pirazol-3(2H)-ona, su preparación y uso terapéutico como activadores de HIF
EP2417123A2 (en) 2009-04-06 2012-02-15 Agios Pharmaceuticals, Inc. Therapeutic compositions and related methods of use
CA2944788C (en) 2009-06-29 2023-08-22 Agios Pharmaceuticals, Inc. Compounds, and compositions thereof, which modulate pyruvate kinase m2, and methods of making same
EP2448581B1 (en) 2009-06-29 2016-12-07 Agios Pharmaceuticals, Inc. Therapeutic compositions and related methods of use
CN102884068A (zh) * 2010-03-15 2013-01-16 国立大学法人广岛大学 噻吩并吡啶衍生物及其制备方法、以及使用该衍生物的有机半导体器件
JP5743418B2 (ja) * 2010-04-09 2015-07-01 Ｏａｔアグリオ株式会社 新規なピラゾール化合物、その製造方法及び有害生物防除剤
ES2770575T3 (es) 2010-10-28 2020-07-02 Pacira Pharmaceuticals Inc Formulación de liberación sostenida de un fármaco antiinflamatorio no esteroideo
EP3053925A1 (en) 2010-12-16 2016-08-10 F. Hoffmann-La Roche AG Tricyclic pi3k inhibitor compounds and methods of use
JP5837091B2 (ja) 2010-12-17 2015-12-24 アジオス ファーマシューティカルズ， インコーポレイテッド ピルビン酸キナーゼｍ２（ｐｋｍ２）調節剤としての新規ｎ−（４−（アゼチジン−１−カルボニル）フェニル）−（ヘテロ−）アリールスルホンアミド誘導体
JP6092118B2 (ja) 2010-12-21 2017-03-08 アジオス ファーマシューティカルズ， インコーポレイテッド ニ環式ｐｋｍ２活性化剤
TWI549947B (zh) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
US8653089B2 (en) 2011-02-09 2014-02-18 F. Hoffmann-La Roche Ag Heterocyclic compounds and methods of use
KR101873543B1 (ko) 2011-05-03 2018-07-02 아지오스 파마슈티컬스 아이엔씨. 치료에 사용하기 위한 피루베이트 키나아제 활성제
WO2012151440A1 (en) 2011-05-03 2012-11-08 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia
US9446175B2 (en) 2011-06-03 2016-09-20 Yale University Compositions and methods for treating and preventing neointimal stenosis
CN102660253B (zh) * 2012-03-07 2014-05-21 泰山医学院 一种吡唑啉衍生物类Ni2+荧光探针及其应用
ES2834959T3 (es) 2012-12-06 2021-06-21 Celgene Quanticel Res Inc Inhibidores de histona desmetilasa
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
MX2015017640A (es) * 2013-06-20 2016-09-07 Basf Se Proceso para preparar compuestos de piridilpirazol y sus derivados de piridilhidrazina.
DK3307271T3 (da) 2015-06-11 2023-10-09 Agios Pharmaceuticals Inc Fremgangsmåder til anvendelse af pyruvatkinase-aktivatorer
WO2017100782A1 (en) 2015-12-11 2017-06-15 Research Institute At Nationwide Children's Hospital Systems and methods for optimized patent specific tissue engineering vascular grafts
KR102434226B1 (ko) * 2016-06-30 2022-08-19 한미약품 주식회사 Alk5 억제제로서의 신규 피라졸 유도체 및 이의 용도
WO2018064441A1 (en) * 2016-09-30 2018-04-05 Intercept Pharmaceuticals, Inc Crystalline forms of a bile acid derivative
EP3541815A4 (en) 2016-11-18 2020-07-15 Pacira Pharmaceuticals, Inc. ZINC MELXICAM COMPLEX MICROPARTICLE MULTIVESICULAR LIPOSOME FORMULATIONS AND METHODS OF MAKING THE SAME
IL298928A (en) * 2020-06-30 2023-02-01 Dermira Inc RORγt INHIBITORS AND TOPICAL USES THEREOF
CN116249692B (zh) * 2020-09-28 2024-08-23 四川科伦博泰生物医药股份有限公司 吡唑类化合物及其制备方法和用途
CA3217735A1 (en) * 2021-05-03 2022-11-10 David A. Bullough Methods for treating a pulmonary disease with an alk-5 (tgf beta r1) inhibitor
EP4514325A1 (en) * 2022-04-29 2025-03-05 MannKind Corporation Method and composition for treating lung diseases
US20250134875A1 (en) * 2023-10-25 2025-05-01 Thirona Bio, Inc. Formulations of alk-5 kinase inhibitors and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0102672D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
UA80571C2 (en) * 2002-11-22 2007-10-10 Lilly Co Eli Quinolinyl-pyrrolopyrazoles
SE0300120D0 (sv) * 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
CL2004000234A1 (es) * 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
AR048669A1 (es) * 2004-03-03 2006-05-17 Syngenta Ltd Derivados biciclicos de bisamida
EP1786803A1 (en) * 2004-08-31 2007-05-23 Biogen Idec MA, Inc. Pyrimidinylpyrazoles as tgf-beta inhibitors
US7511056B2 (en) * 2004-11-10 2009-03-31 Eli Lilly And Company TGF-β inhibitors
CN101528752A (zh) * 2006-10-16 2009-09-09 辉瑞产品公司 治疗性吡唑基噻吩并吡啶

Also Published As

Publication number Publication date
TW200825094A (en) 2008-06-16
AU2007311560A1 (en) 2008-04-24
ES2435430T3 (es) 2013-12-19
EP2527345A1 (en) 2012-11-28
US9090625B2 (en) 2015-07-28
US20150175624A1 (en) 2015-06-25
UY30641A1 (es) 2008-05-31
US20140031385A1 (en) 2014-01-30
AR063318A1 (es) 2009-01-21
CN101528752A (zh) 2009-09-09
IL197750A0 (en) 2009-12-24
US9260450B2 (en) 2016-02-16
EP2074128B1 (en) 2013-08-14
EP2527345B1 (en) 2015-12-16
AU2007311560B2 (en) 2011-04-21
CA2666603A1 (en) 2008-04-24
US20110224251A1 (en) 2011-09-15
EP2074128A1 (en) 2009-07-01
CL2007002916A1 (es) 2008-04-18
ES2559521T3 (es) 2016-02-12
US20080090861A1 (en) 2008-04-17
MX2009003157A (es) 2009-04-03
KR20090066297A (ko) 2009-06-23
WO2008047198A1 (en) 2008-04-24
US8455512B2 (en) 2013-06-04
JP5443988B2 (ja) 2014-03-19
JP2010506895A (ja) 2010-03-04
CA2666603C (en) 2013-08-06
US20160200735A1 (en) 2016-07-14
US7964612B2 (en) 2011-06-21
US9938289B2 (en) 2018-04-10

Similar Documents

Publication Publication Date Title
NO20091247L (no) terapeutiske pyrazolyl tienopyridiner
NO20062704L (no) Azabicykliske heterocykler som cannabinoide reseptormodulatorer
NO20090025L (no) Pyrrolotriazinkinaseinhibitorer
NO20070557L (no) Ftalazinderivater som PARP-inhibitorer
NO20062691L (no) Azabicykliske heterocykler som cannabinoide reseptormodulatorer
PT1984357E (pt) Compostos de 2,4-pirimidinadiamina para tratamento ou prevenção de doenças autoimunes
NO20083207L (no) Inhibitorer av IAP
NO20062689L (no) Azabisykliske heterosykler som modulatorer for kannabinoidreseptorer
NO20076357L (no) Azabicykliske heterocykler som cannabinoid reseptor modulatorer
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
NO20070529L (no) Kinazolindionderivater som parp-inhibitorer
NO20070555L (no) Kinazolinonderivater som parp-inhibitorer
NO20082136L (no) 1,5-substituerte indol-2-yl-amidderivater
NO20082096L (no) Azaindol-2-karboksamidderivativer
NO20084489L (no) Azolopyrimidiner som inhibitorer av cannabinoid 1 aktivitet
NO20074275L (no) 2- (4-okso-4H-kinazolin-3-yl) acetamider og deres anvendelse som Vasopressin-V3-antagonister
NO20083717L (no) Pyrrolotriazin-anilin prodrugforbindelser anvendbare som kinaseinhibitorer
NO20075082L (no) Pyridin-3-karboksamidderivater som CB1-inversagonister
NO20070323L (no) Organiske forbindelser
NO20084129L (no) Pyridin(3,4-B)Pyrazinoner
TW200714604A (en) Substituted heterocycles and the uses thereof
NO20071617L (no) Indozolonderivater som 11B-HSD1-inhibitorer
NO20081844L (no) Terapeutiske forbindelser
NO20070445L (no) Pyrimidinderivater.
NO20072608L (no) Biaryloksymetylarenkarboksylsyrer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application